Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bristol Myers Squibb Co (NYSE:BMY) is the #1 top healthcare stock out of 1060 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 50, which is 24 points higher than the healthcare sector average of 26. It passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 42.72% over the past year, overperforming other healthcare stocks by 138 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $67.40, an upside of 0.18% from Bristol Myers Squibb Co's current stock price of $67.28.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Bristol Myers Squibb Co, 54.55% have issued a Strong Buy rating, 0% have issued a Buy, 45.45% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Puma Biotechnology (NASDAQ:PBYI) is the #2 top healthcare stock out of 1060 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: C, Momentum: A, Sentiment: B, Safety: C, Financials: A, and AI: C.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 52, which is 26 points higher than the healthcare sector average of 26. It passed 16 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock return 82.77% over the past year, overperforming other healthcare stocks by 178 percentage points.

Puma Biotechnology has an average 1 year price target of $6.00, a downside of -34.21% from Puma Biotechnology's current stock price of $9.12.

Puma Biotechnology stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Electromed (NYSEMKT:ELMD) is the #3 top healthcare stock out of 1060 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Electromed (NYSEMKT:ELMD) is: Value: C, Growth: B, Momentum: B, Sentiment: A, Safety: B, Financials: A, and AI: C.

Electromed (NYSEMKT:ELMD) has a Due Diligence Score of 49, which is 23 points higher than the healthcare sector average of 26. It passed 17 out of 33 due diligence checks and has strong fundamentals. Electromed has seen its stock return 99.46% over the past year, overperforming other healthcare stocks by 195 percentage points.

Electromed has an average 1 year price target of $40.00, a downside of -0.72% from Electromed's current stock price of $40.29.

Electromed stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Electromed, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 78 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Cumberland Pharmaceuticals (NASDAQ:CPIX) has an annual dividend yield of 38.27%, which is 36 percentage points higher than the healthcare sector average of 2.62%.

Cumberland Pharmaceuticals's dividend payout ratio of -411% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 20.41%, which is 18 percentage points higher than the healthcare sector average of 2.62%.

Siga Technologies's dividend payout ratio of -1,500% indicates that its high dividend yield might not be sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 11.75%, which is 9 percentage points higher than the healthcare sector average of 2.62%. Spok Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 207.9% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -0.34% in the last day, and up 2.19% over the last week. Regenxbio was the among the top losers in the healthcare sector, dropping -24.86% yesterday.

REGENXBIO shares are trading lower after the company announced that the FDA placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 71, which is 57 points higher than the healthcare sector average of 14. It passed 5 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 225.2% in the past year. It has overperformed other stocks in the healthcare sector by 320 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 43 points higher than the healthcare sector average of 14. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 2.89% in the past year. It has overperformed other stocks in the healthcare sector by 98 percentage points.

Exelixis (NASDAQ:EXEL) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Exelixis has a valuation score of 29, which is 15 points higher than the healthcare sector average of 14. It passed 2 out of 7 valuation due diligence checks.

Exelixis's stock has gained 43.93% in the past year. It has overperformed other stocks in the healthcare sector by 139 percentage points.

61.34% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 24.13% over the next year.

4.84% of healthcare stocks have a Zen Rating of A (Strong Buy), 13.15% of healthcare stocks are rated B (Buy), 46.28% are rated C (Hold), 28.29% are rated D (Sell), and 7.44% are rated F (Strong Sell).